Leisure Sedentary Time Linked to Prevalence of Uterine Fibroids
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 29, 2023 -- Leisure sedentary time (LST) is independently associated with the prevalence of uterine fibroids (UFs), according to a study published online Nov. 28 in BMJ Open.
Yunrui Sun, from the School of Public Health at Kunming Medical University in China, and colleagues conducted a cross-sectional analysis of data from 6,623 nonmenopausal women aged 30 to 55 years old from the China Multi-Ethnic Cohort Study to examine the association between LST and UFs.
Overall, 562 participants had UFs, with prevalence of 8.5 percent. The researchers found that the risk for UFs was 2.008 times higher for women with LST at least six versus less than two hours/day in a multivariate adjusted logistic regression analysis. A linear dose-response relationship between LST and UFs was seen in restricted cubic spline results. A correlation between LST and UFs was only seen in women with a body mass index <24 kg/m2 or perimenopausal women, according to the results of a stratified analysis.
"Although our study contains some limitations, taken together, the results show a relatively clear relationship between leisure sedentary behavior and UFs, and this study can provide information for exploring the etiology of UFs in the future," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-30 00:33
Read more
- Supply Chain Issues Less Likely to Yield Drug Shortages in Canada Versus U.S.
- Cataract Surgery Could Save Your Eyesight and Maybe Your Life
- Globally, Suicide Risk Increased on Certain Days of the Week, Holidays
- AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
- Medication Abortion Before Confirmed Intrauterine Pregnancy Noninferior
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions